Actively Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-02-24
60
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
Sponsors
I
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
H
Henan Cancer Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
CONDITIONS
Official Title
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6-18 years old, male or female
- Diagnosed with primary immune thrombocytopenia (ITP)
- Previously treated with eltrombopag and switched to avatrombopag due to poor effectiveness, large platelet fluctuations, intolerance, patient preference, economic reasons, or other causes
- New York Society of Cardiac Function score of 2 or less
- Understands the study procedures and voluntarily signs informed consent
You will not qualify if you...
- Secondary thrombocytopenia from causes like connective tissue disorders, bone marrow failure, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, immune deficiency, lymphoma, etc.
- Primary disease affecting major organs (liver, kidney, heart) or immune system diseases
- Known allergy to avatrombopag or its excipients
- Use of rituximab within the last 3 months
- Splenectomy within the last 3 months
- History of abnormal platelet aggregation affecting platelet count reliability
- Any medical condition deemed unsuitable for study participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, China
Actively Recruiting
Research Team
L
Lei Zhang, MD
CONTACT
T
Ting Sun, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here